KR20220009416A - 칸디다 아우리스 탈집락화를 위한 항진균제 - Google Patents

칸디다 아우리스 탈집락화를 위한 항진균제 Download PDF

Info

Publication number
KR20220009416A
KR20220009416A KR1020217040747A KR20217040747A KR20220009416A KR 20220009416 A KR20220009416 A KR 20220009416A KR 1020217040747 A KR1020217040747 A KR 1020217040747A KR 20217040747 A KR20217040747 A KR 20217040747A KR 20220009416 A KR20220009416 A KR 20220009416A
Authority
KR
South Korea
Prior art keywords
candida auris
compound
formula
candida
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217040747A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 앙굴로 곤잘레스
스티븐 앤드류 바라트
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20220009416A publication Critical patent/KR20220009416A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020217040747A 2019-05-16 2020-05-12 칸디다 아우리스 탈집락화를 위한 항진균제 Pending KR20220009416A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16
US62/849,019 2019-05-16
PCT/US2020/032547 WO2020232037A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Publications (1)

Publication Number Publication Date
KR20220009416A true KR20220009416A (ko) 2022-01-24

Family

ID=70861571

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040747A Pending KR20220009416A (ko) 2019-05-16 2020-05-12 칸디다 아우리스 탈집락화를 위한 항진균제

Country Status (14)

Country Link
US (1) US20220211684A1 (https=)
EP (1) EP3968986A1 (https=)
JP (2) JP7770191B2 (https=)
KR (1) KR20220009416A (https=)
CN (1) CN113905733A (https=)
AU (1) AU2020276595B2 (https=)
BR (1) BR112021022876A2 (https=)
CA (1) CA3140637A1 (https=)
EA (1) EA202193146A1 (https=)
IL (1) IL288165B1 (https=)
MA (1) MA55958A (https=)
MX (1) MX2021013899A (https=)
TW (2) TWI881977B (https=)
WO (1) WO2020232037A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
MA43825A (fr) * 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association
AU2018269892A1 (en) * 2017-05-17 2019-11-28 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of Candida species
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제
US20220117948A1 (en) * 2019-01-30 2022-04-21 Scynexis, Inc. Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Also Published As

Publication number Publication date
CN113905733A (zh) 2022-01-07
TW202110441A (zh) 2021-03-16
EA202193146A1 (ru) 2022-02-11
US20220211684A1 (en) 2022-07-07
CA3140637A1 (en) 2020-11-19
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
EP3968986A1 (en) 2022-03-23
AU2020276595A1 (en) 2021-12-09
AU2020276595B2 (en) 2025-12-04
TWI881977B (zh) 2025-05-01
WO2020232037A1 (en) 2020-11-19
JP2025118765A (ja) 2025-08-13
BR112021022876A2 (pt) 2022-04-12
JP2022532734A (ja) 2022-07-19
TW202602460A (zh) 2026-01-16
JP7770191B2 (ja) 2025-11-14
MA55958A (fr) 2022-03-23
IL288165A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US9839634B2 (en) Antibacterial agents: combination of a rifamycin and a switch region inhibitor
JP7574268B2 (ja) 併用される抗真菌剤
AU2024227501A1 (en) Antifungal agents with enhanced activity in acidic pH
JP2025118765A (ja) カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤
JP5132569B2 (ja) フェニルアミジン誘導体を含有する医薬組成物および抗真菌剤を組み合わせて使用する方法
KR20080052648A (ko) 옥사졸 화합물을 포함하는 항결핵 조성물
US20250248983A1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
CN113332277B (zh) 一种吡咯二酮化合物在制备抗真菌药物中的应用
HK40067174A (zh) 用於消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂
EA048874B1 (ru) Противогрибковые агенты для деколонизации candida auris
JP2022523212A (ja) ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬
EA051506B1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций
WO2003066049A1 (en) Combinations for the treatment of fungal infections
HK40022879B (en) Antifungal agents used in combination

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000